• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Leena Gandhi

Publications

  • Chung V, Shibata SI, Synold TW, Longmate J, Suttle AB, Ottesen LH, Lenz HJ, Kummar S, Harvey RD, Hamilton A, O'Neil BH, Sarantopoulos J, Lorusso PM, Rudek MA, Dowlati A, Mulkerin D, Belani CP, Gandhi L, Lau C, Ivy P, Newman EM.Phase 1 Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.Clin Cancer Res. 2013 May 7.
    23653147
  • Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M.Small cell lung cancer.J Natl Compr Canc Netw. 2013 Jan 1;11(1):78-98.
    23307984
  • Gandhi L, Drappatz J, Ramaiya NH, Otterson GA.High-dose pemetrexed in combination with high-dose crizotinib for the treatment of refractory CNS metastases in ALK-rearranged non-small-cell lung cancer.J Thorac Oncol. 2013 Jan;8(1):e3-5.
    23242445
  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT.Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.Lancet Oncol. 2012 Oct;13(10):1011-9.
    22954507
  • Gandhi L, Jänne PA.Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target.Clin Cancer Res. 2012 Jul 15;18(14):3737-42.
    22547770
  • Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L.Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Clin Cancer Res. 2012 Jun 1;18(11):3163-9.
    22496272
  • Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM.Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors.J Clin Oncol. 2011 Mar 1;29(7):909-16.
    21282543
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ.Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010 Oct 28;363(18):1693-703.
    20979469
  • Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR.Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer.Cancer Epidemiol Biomarkers Prev. 2010 May;19(5):1362-72.
    20447926
  • Gandhi L,McNamara KL,Li D,Borgman CL,McDermott U,Brandstetter KA,Padera RF,Chirieac LR,Settleman JE,Wong KK.Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis.Cancer Prev Res (Phila Pa). 2009 Apr;2(4):330-7.
    19336729
  • Engelman JA, Zejnullahu K, Gale CM, Lifshits E, Gonzales AJ, Shimamura T, Zhao F, Vincent PW, Naumov GN, Bradner JE, Althaus IW, Gandhi L, Shapiro GI, Nelson JM, Heymach JV, Meyerson M, Wong KK, Jnne PA.PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.Cancer Res. 2007 Dec 15;67(24):11924-32.
    18089823
  • Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, Johnson BE, Lynch TJ.A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.Cancer. 2007 Mar 1;109(5):924-32.
    17285598
  • Gandhi L, Johnson BE.Paraneoplastic syndromes associated with small cell lung cancer.J Natl Compr Canc Netw. 2006 Jul;4(6):631-8. Review.
    16813730